SS-31
Elamipretide — a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane and binds cardiolipin. In clinical trials for heart failure and mitochondrial disease.
SS-31 (Elamipretide, MTP-131) is a synthetic tetrapeptide that selectively concentrates in the inner mitochondrial membrane (IMM) at a ratio approximately 5,000-fold over cytosol. Its primary mechanism involves high-affinity binding to cardiolipin — the signature phospholipid of the inner mitochondrial membrane critical for electron transport chain function.
Cardiolipin plays a structural and functional role in organizing electron transport chain complexes into supercomplexes that optimize ATP production efficiency. Age, disease, and metabolic stress are associated with cardiolipin oxidation and redistribution, disrupting ETC function. SS-31 is proposed to stabilize cardiolipin and restore ETC efficiency.
Clinical trials have investigated SS-31/elamipretide in heart failure (STARGLO and LEAF trials) and rare mitochondrial diseases. These provide human safety data but efficacy results have been mixed. Physician practice use for longevity extrapolates from the disease-context data.
What are you researching?
Tell us your focus area and we’ll send a personalized research guide.
SS-31/Elamipretide is not FDA-approved for any indication. Research use only. Injection site reactions are the primary adverse effect reported in clinical trials. Not currently WADA-prohibited (verify current list). All information for educational reference only.